Last ¥1,809 JPY
Change Today -1.00 / -0.06%
Volume 6.5M
4503 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 1:00 AM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc (4503) Snapshot

Open
¥1,780
Previous Close
¥1,810
Day High
¥1,817
Day Low
¥1,780
52 Week High
11/4/14 - ¥1,842
52 Week Low
04/14/14 - ¥1,062
Market Cap
4.1T
Average Volume 10 Days
7.2M
EPS TTM
--
Shares Outstanding
2.3B
EX-Date
03/27/15
P/E TM
--
Dividend
¥30.00
Dividend Yield
1.55%
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., and Dana-Farber Cancer Institute. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,649 Employees
Last Reported Date: 06/18/14
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

astellas pharma inc (4503) Key Developments

Medivation, Inc. and Astellas Pharma Inc. Announces Topline Results from Phase 2 Terrain Trial

Medivation, Inc. and Astellas Pharma Inc. announced topline results from the Phase 2 TERRAIN trial comparing enzalutamide with bicalutamide in men with metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared to bicalutamide (Hazard Ratio = 0.44; 95% Confidence Interval, 0.34-0.57; p < 0.0001). Median PFS was 15.7 months in the enzalutamide group compared to 5.8 months in the bicalutamide group. The median time on treatment in TERRAIN was 11.7 months in the enzalutamide group versus 5.8 months in the bicalutamide group. Serious adverse events were reported in 31.1% of enzalutamide-treated patients and 23.3% of bicalutamide-treated patients. Grade 3 or higher cardiac adverse events were reported in 5.5% of enzalutamide-treated patients versus 2.1% of bicalutamide-treated patients. Two seizures were reported in the enzalutamide group and one in the bicalutamide group. The most common side effects occurring during treatment and more common in the enzalutamide-treated versus bicalutamide-treated patients included fatigue, hot flush, hypertension, diarrhea, weight decreased and pain in extremity.

Astellas Pharma Inc. Hires Global Executive Eric Terhaerdt to Lead Global Development Operations

Astellas Pharma Inc. announced that Eric Terhaerdt has been named senior vice president of Global Development Operations. Terhaerdt will be located at Astellas' headquarters for the Americas in Northbrook, Ill., USA, and will report to Dr. Bernie Zeiher, executive vice president, Global Development and Therapeutic Area head: Immunology, Infectious Disease, Transplantation and Central Nervous System and Pain, with Astellas Pharma Global Development, Inc. Terhaerdt will be responsible for establishing the global direction of the drug development operations of Astellas in The Netherlands and the U.S. and will work closely with Japan Development Operations to ensure global operational effectiveness and efficiency. As a key direct report to the executive vice president of Global Development, he will play an instrumental role in defining development strategy and ensuring the effective and efficient development of the Astellas product portfolio. Terhaerdt spent over 20 years with AstraZeneca, serving in a variety of global leadership roles with increasing responsibility, in the areas of clinical research, clinical development, clinical quality, strategy and performance and scientific and technical evaluations.

Astellas Pharma, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 02:00 PM

Astellas Pharma, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 02:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Yoshihiko Hatanaka, Chief Executive Officer, President and Representative Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4503:JP ¥1,809.00 JPY -1.00

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $70.66 USD 0.00
Becton Dickinson and Co $142.22 USD 0.00
CSL Ltd A$87.12 AUD +0.70
Mylan Inc/PA $56.30 USD 0.00
Takeda Pharmaceutical Co Ltd ¥5,805 JPY +18.00
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 33.3x
Price/Sales 3.2x
Price/Book 2.9x
Price/Cash Flow 22.9x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.